IP Library Patent Application 14376204
Patent Application
App. No. 14/376,204

Novel Screening Methods

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
14/376,204
Abstract

The present invention includes a luciferase-based high-throughput screening assay that identifies compounds that are inhibitors of cellular metabolism. This assay is applicable to all bacterial and eukaryotic membranes.

Claims (21)

1 . A method of identifying a compound that inhibits cellular metabolism, the method comprising the steps of:

(a) isolating a membrane from a cell having a functional oxidative phosphorylation pathway;

(b) contacting an aliquot of the isolated membrane with a test compound to yield a first mixture;

(c) contacting an aliquot of the isolated membrane with a control compound to yield a second mixture;

(d) adding luciferase to the first mixture and to the second mixture;

(e) measuring the level of luminescence emitted from the first and second mixtures,

wherein, if the level of luminescence in the first mixture is lower than the level of luminescence in the second mixture, the test compound is identified as inhibiting cellular metabolism.

2 . The method of claim 1 , wherein the level of luminescence in the first mixture is less than about 70% of the level of luminescence in the second mixture.

3 . The method of claim 1 , wherein the test compound inhibits or disrupts the activity of at least one enzyme in the oxidative phosphorylation pathway in the cell.

4 . The method of claim 1 , wherein the test compound inhibits or disrupts the proton motive force (H + gradient) altering the electrochemical gradient across the cellular membrane affecting the proton concentration across the membrane.

5 . The method of claim 1 , wherein the test compound inhibits or disrupts the difference in electric potential across the cellular membrane.

6 . The method of claim 1 , wherein the cell is eukaryotic.

7 . The method of claim 6 , wherein the eukaryotic cell is mammalian.

8 . The method of claim 1 , wherein the cell is bacterial.

9 . The method of claim 8 , wherein the bacterium is Gram positive.

10 . The method of claim 9 , wherein the Gram positive bacterium is selected from the group consisting of Staphylococcus aureus, Mycobacterium smegmatis, Bacillus thuringiensis, Enterococcus , and combinations thereof.

11 . The method of claim 8 , wherein the bacterium is Gram negative.

12 . The method of claim 11 , wherein the Gram negative bacterium is selected from the group consisting of Acinetobacter baumannii, Pseudomonas aeruginosa, Yersinia enterocolitica, Escherichia coli, Klebsiella pneumonia , and combinations thereof.

13 . The method of claim 1 , wherein the luciferase is added at the beginning of the assay.

14 . The method of claim 1 , wherein the assay is carried out over a period of time of two hours or less.

15 . The method of claim 1 , wherein the volume of assay reactions ranges from about 5 μL to about 20 μL.

Assignments (2)
CONFIRMATORY LICENSE Recorded Dec 13, 2018
From: UNIVERSITY OF PENNSYLVANIA
To: NATIONAL INSTITUTES OF HEALTH-DIRECTOR DEITR
Reel/Frame 047773/0278 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 24, 2015
From: RUBIN, HARVEY; YANO, TAKAHIRO
To: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
Reel/Frame 035016/0928 →